Theseus Pharmaceuticals shares are trading lower after the company reported initial dose escalation data from the ongoing phase 1/2 trial of THE-630 in patients with advanced GIST.
Portfolio Pulse from Benzinga Newsdesk
Theseus Pharmaceuticals reported initial dose escalation data from the ongoing phase 1/2 trial of THE-630 in patients with advanced GIST, causing its shares to trade lower.
May 26, 2023 | 12:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Theseus Pharmaceuticals' shares are trading lower after reporting initial dose escalation data from the ongoing phase 1/2 trial of THE-630 in patients with advanced GIST.
The initial dose escalation data from the ongoing phase 1/2 trial of THE-630 in patients with advanced GIST is a significant event for Theseus Pharmaceuticals. As the shares are trading lower after the news, it indicates that the market may have perceived the data as negative or not meeting expectations, leading to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100